Ms. Kiddell-Monroe, I want to pick up on something you said that I think is very important. You talked about exclusivity and non-exclusivity, and I think that really goes to the heart of what we're trying to discuss here.
Just so that it will be on the record, could you expand on your idea of global access licensing, the difference between exclusivity and non-exclusivity, and why you feel non-exclusivity would really make such a big difference in drug pricing?